To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
febit Receives European Union Patent for Synthesis of Minimal Genomes
Read time: Less than a minute
febit announced the receipt of an EU patent, #EP 1 728 860B1, for its technology to synthesize minimal genomes.
The new patent protects febit’s technology for combining genes to construct a minimal functional genome or parts of it. The EU patent complements earlier patents on the synthesis of oligonucleotides for gene-assembling.
A minimal genome contains only the genetic information which is required to sustain life of a certain organism under predefined conditions. Minimal genomes help to identify essential genes and investigate the isolated activity of interesting genes in minimal cells. The synthesis of minimal genomes complements febit’s portfolio which contains groundbreaking technologies for the exploration of the genome. HybSelect, for example, is a technology for the enrichment of interesting genes for targeted resequencing. febit’s miRNA profiling enables the discovery and evaluation of new biomarker signatures for various diseases.
The new patent protects febit’s technology for combining genes to construct a minimal functional genome or parts of it. The EU patent complements earlier patents on the synthesis of oligonucleotides for gene-assembling.
A minimal genome contains only the genetic information which is required to sustain life of a certain organism under predefined conditions. Minimal genomes help to identify essential genes and investigate the isolated activity of interesting genes in minimal cells. The synthesis of minimal genomes complements febit’s portfolio which contains groundbreaking technologies for the exploration of the genome. HybSelect, for example, is a technology for the enrichment of interesting genes for targeted resequencing. febit’s miRNA profiling enables the discovery and evaluation of new biomarker signatures for various diseases.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
